Category Archives: Health: Addiction

Addiction one of the Largest growing Problem’s in the world today. This Press Release Service will bring you the newest services and research available.

Yuba City Natives Join RejuvenI & Hodari MD Dermatology to Offer Best-in-Class Skincare Services


RejuvenI & Hodari MD Dermatology is proud to welcome Ramneet Basra, PA-C, and Rubeena Basra, BSN to their team of skilled skincare providers. Born and raised in Yuba City, these sisters have returned to their hometown to provide exceptional cosmetic dermatology services to the community.

YUBA CITY, Calif., Sept. 12, 2023 /PRNewswire-PRWeb/ — Yuba City Natives Join RejuvenI & Hodari MD Dermatology to Offer Best-in-Class Skincare Services

Yuba City, CARejuvenI & Hodari MD Dermatology is proud to welcome Ramneet Basra, PA-C, and Rubeena Basra, BSN to their team of skilled skincare providers. Born and raised in Yuba City, these sisters have returned to their hometown to provide exceptional cosmetic dermatology services to the community.

After working as a physician assistant in a local hospital’s emergency room for three years, Ramneet Basra found her passion in dermatology. She completed her training at the Massachusetts College of Pharmacy and Health Sciences in Boston, MA before returning to Yuba City to join Dr. Kafele Hodari’s dermatology practice. Ramneet’s experience in emergency medicine has given her the skills to diagnose and manage a range of medical conditions, including skin diseases. She is passionate about helping her patients feel beautiful and powerful in their skin.

Working alongside Dr. Hodari, Ramneet helps patients develop a comprehensive skincare regimen that includes laser skin treatments, BOTOX, and dermal fillers. As a member of the American Academy of PAs, Ramneet is committed to providing the highest level of care to her patients.

Rubeena Basra, BSN is a registered nurse and a certified nurse injector specializing in cosmetic injectables such as neurotoxins and dermal fillers. She has a background in dermatology and is passionate about helping patients achieve healthy, glowing skin. Her gentle touch and attention to detail ensure that patients leave feeling refreshed and rejuvenated.

RejuvenI & Hodari MD Dermatology offers a wide range of cosmetic dermatology services, including BOTOX, dermal fillers, laser procedures, micro-needling, facials, Body Sculpting and more. Patients can trust that they will receive personalized care and attention from Ramneet, Rubeena, and the rest of the skilled team at Hodari MD Dermatology.

Located just minutes from the intersection of Highway 99 and Colusa Avenue, RejuvenI & Hodari MD serves cosmetic and medical dermatology patients from throughout Sutter County. To schedule an appointment, visit rejuvene.com or call 530.561.5929.

For more information about RejuvenI & Hodari MD Dermatology and its services, visit rejuvenI.com.

Contact: Jennifer Thomson

Address: 1178 Live Oak Blvd, Yuba City, CA 95991

Phone: 530.561.5929

Website: rejuvenI.com

Media Contact

Nichole Volk, PhyNet Dermatology, LLC, 1 6156300805, [email protected], phynet.com

SOURCE PhyNet Dermatology, LLC

Surgical Outcomes of Perioperative Durvalumab in AEGEAN Study to be Presented at IASLC 2023 World Conference on Lung Cancer


The AEGEAN trial is a double-blind, placebo-controlled phase 3 study that evaluated the use of perioperative durvalumab in combination with neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone. The trial involved adults with treatment-naïve resectable NSCLC (stage II-IIIB[N2]; AJCC 8th ed) and ECOG PS 0/1. Patients were randomized to receive either neoadjuvant durvalumab 1500 mg or placebo intravenously (IV) alongside platinum-based CT prior to surgery. Following surgery, patients received durvalumab 1500 mg or placebo IV, respectively. The primary endpoints of the trial were pathological complete response and event-free survival.

The study randomized 802 patients with treatment- naïve resectable NSCLC (stage II-IIIB[N2] and ECOG PS 0/1). Efficacy analyses were performed in the modified intent-to-treat population which comprised 740 patients with no documented EGFR mutations/ALK gene rearrangements (366 in the durvalumab arm and 374 in the placebo arm).

Lobectomy, sleeve resection, or bilobectomy were allowed as planned surgery (at enrolment); the protocol was amended with enrollment ongoing to exclude patients with tumors classified as T4 for any reason other than size (>7 cm) or whose planned surgery was pneumonectomy (originally allowed).

In the modified intent-to-treat population, 80.6% and 80.7% underwent surgery, respectively; 77.6% and 76.7% completed surgery, with disease progression the most common reason for canceled (6.8% vs 7.8%) or non-completed (1.4% vs 2.1% ) surgery. Among treated patients who underwent surgery, 17.3% and 22.2% had delayed surgery, most commonly for logistical reasons (e.g., scheduling issues; 9.5% vs. 12.3%). The median time from the last neoadjuvant treatment dose to surgery was the same in each arm (34.0 days). Among patients who underwent surgery, similar proportions in the durvalumab and placebo arms had open (49.2% vs 50.7%) and minimally invasive procedures (49.2% vs 47.0%); lobectomy (including sleeve resection and bilobectomy) was the most common procedure (88.1% vs 85.4%), followed by pneumonectomy (9.2% vs 9.6%). Among patients who completed surgery, a numerically higher proportion had R0 resection in the durvalumab versus placebo arm (94.7% vs 91.3%).

According to Dr. Mitsudomi, it is encouraging to see these comprehensive outcomes described in a robust phase 3 trial which showed that adding perioperative durvalumab to neoadjuvant CT did not adversely impact the feasibility, type, extent, or timing of surgery in patients with R-NSCLC and was associated with a tolerable surgical safety profile. Further, the addition of durvalumab resulted in numerically higher R0 resection rates.

AEGEAN data from outcomes for patients with documented EGFR mutations are also being presented at IASLC 2023 World Conference on Lung Cancer.

The AEGEAN study was conducted by AstraZeneca (LSE/STO/Nasdaq: AZN).

About the IASLC:

 The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

About the WCLC:

 The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org  

Media Contact

Chris Martin, The David James Group, 6306702745, [email protected], https://wclc2023.iaslc.org

SOURCE International Association for the Study of Lung Cancer

U.S. Dermatology Partners Announces the Opening of St. Joseph, Missouri Office


“For patients in rural areas, accessing dermatological care can be challenging due to extended wait times or the need to travel long distances to reach the nearest practitioners,” said Paul Singh, Chief Executive Officer of U.S. Dermatology Partners. “We are pleased to offer more accessible care options to patients in St. Joseph through the expansion of our Outreach Program. We look forward to serving the residents of Andrew and Buchanan Counties with the quality dermatologic care they deserve.”

St. Joseph is located in Andrew and Buchanan County and is the county seat of Buchanan County. Located at the crossroads of Interstate 29 and Highway 36, St. Joseph is only 30 minutes from North Kansas City. The city is home to 13 distinctive area museums, 12 annual festivals, architecture listed on the National Register of Historic Places, and the Kansas City Chiefs Summer Training Camp. Residents of St. Joseph also enjoy outdoor recreation throughout 48 parks, 26 miles of beautiful walking paths, outdoor concerts, and an active arts and culture scene.

Today’s announcement builds on U.S. Dermatology Partners’ recent openings of offices in Olathe, Kansas, Canton, Texas, and Frederick, Maryland. The St. Joseph office is conveniently located at 3107 Frederick Ave., #B, St. Joseph, Missouri, 64506. For more information or to schedule an appointment call (816) 205-4123 or click here to request an appointment online.

About U.S. Dermatology Partners
U.S. Dermatology Partners is one of the premier dermatology practices in the country, caring for nearly two million patients each year. With over 100 locations across eight states that span large metroplexes and rural, underserved communities, they provide the benefits of private, personalized levels of care paired with a network of coordinated, specialized dermatology physicians. U.S. Dermatology Partners is fervently focused on providing the highest level of compassionate and comprehensive patient-first care, making it seamless for all people to connect with dermatologists and national leaders in areas such as clinical research, psoriasis, and Mohs surgery and gain access to state-of-the-art dermatological treatments, surgical and cosmetic dermatology. To learn more, visit usdermatologypartners.com.  

Media Contact

Jeanne Cunningham, U.S. Dermatology Partners, 2144200655, [email protected], www.usdermatologypartners.com

SOURCE U.S. Dermatology Partners

Dr. Thomas McNemar Continues Partnership With Exclusive Haute Beauty Network


Dr. Thomas McNemar attended the Medical College of Ohio, where he decided to pursue a surgical career. After completing a general surgery residency at the prestigious Cleveland Clinic, he continued his surgical education at Akron City Hospital as a plastic surgery fellow. Realizing he possessed a natural gift for detail and perfection, he elected to round out his formal education at the Bunke Clinic in San Francisco, California, as an attending fellow specializing in hand and microvascular surgery. He is a diplomate of the American Board of Plastic Surgery and a Fellow of the American College of Surgeons.

To get to know Dr. McNemar, request a consultation using our online form or call (209) 290-1588 for our Tracy office to make your appointment.

Learn more about Dr. Thomas McNemar by visiting:
https://hauteliving.com/hautebeauty/member/dr-thomas-mcnemar/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Media Contact

Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected], https://hauteliving.com/hautebeauty/

SOURCE Haute Beauty by Haute Living

Decortication and Chemotherapy Associated with Worse Outcomes for Patients with Resectable Mesothelioma


Mesothelioma, a rare and aggressive cancer primarily linked to asbestos exposure, has prompted exploration into various treatment options, including surgical procedures like pleurectomy decortication. However, despite its common use, the effectiveness of this intervention has never been evaluated in a randomized trial.

The trial, which enrolled 335 participants, randomly assigned 169 patients with resectable mesothelioma to extended pleurectomy decortication and 166 patients to chemotherapy (platinum and pemetrexed) or chemotherapy alone.
The researchers followed patients for a median 22.4 months.
Patients randomized to surgery and chemotherapy exhibited a median survival of 19.3 months, while those randomized to chemotherapy alone demonstrated a median survival of 24.8 months. However, the hazards for death were non-proportional, prompting the presentation of primary outcomes in two timeframes: randomization to 42 months and beyond 42 months. The analysis indicated a 28% increase in the risk of death in the surgery group within the first 42 months, while no significant difference in survival emerged after 42 months, Lim reported.

Moreover, the research unveiled significant disparities in progression-free survival and adverse events between the two groups. The surgery group experienced a 3.6-fold higher incidence of serious adverse events (CTCAE grade 3 and above), and Dr. Lim reported that patients who underwent surgery reported poorer quality of life and well-being on various EORTC health-related quality of life scales, particularly in global health, physical functioning, social functioning, and role functioning. The surgery group also exhibited worse positive symptom scores, including pain, dyspnea, insomnia, loss of appetite, and financial difficulties.

Prof. Lim concluded that extended pleurectomy decortication should not be offered to patients with pleural mesothelioma and classifying this disease as “unresectable” from the outset would increase access to more effective systemic treatments to improve survival for patients with early-stage disease.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.

Media Contact

Chris Martin, IASLC, 6306702745, [email protected], https://wclc2023.iaslc.org.

SOURCE IASLC

Caring Transitions Brings Much Needed Services to Pennsylvania


After spending over 20 years in the corporate world, Scott decided he needed a revamp and reboot. He discovered Caring Transitions through his sister, who lives in Arizona. Couple that with caring for an ageing parent himself over the last few months, Scott confessed that the services and support that Caring Transitions offered seemed like a natural fit and met his goal of helping others in any new venture he undertook.

“I understand what families go through and the stress it can put on them when you’re trying to juggle your own life, and also have to deal with an emotional and uncertain situation,” Scott said. “Being able to help a family through a challenging time is really valuable, especially because I see myself eventually needing that with my own parent when there needs to be a different living arrangement.”

Caring Transitions of East Stroudsburg will serve East Stroudsburg, Bushkill, Cresco, Dingman’s Ferry, Hawley, Milford, The Poconos, Stroudsburg, Tobyhanna and surrounding areas. Scott is looking forward to helping minimize stress for families during what can be a difficult time in a loved one’s life.

“Going through a transition like moving for seniors can be challenging and fraught with emotion,” Scott said. “Having someone to lighten the load and take charge of details can be extremely beneficial.”

“Scott is certainly somebody that gets it,” said Ray Fabik, President of Caring Transitions. “He empathizes with clients because he himself has an aging parent. It’s clear he cares about his community and his team will be a valuable asset to anyone in the Stroudsburg area who needs help downsizing or re-focusing their living situation.”

To learn more about Caring Transitions, visit http://www.CaringTransitions.com.

For more about franchising opportunities with Caring Transitions, visit https://www.caringtransitionsfranchise.com/.

About Caring Transitions

Caring Transitions, founded in 2006, is the most trusted and experienced national franchise specializing in senior relocation and transition services. With more than 280 locations throughout the United States, all owned and operated by Certified Relocation and Transition Specialists, Caring Transitions provides clients with supportive moves, auctions, rightsizing, and transitions. This includes expert advice plus a well-executed transition plan beginning with the initial sorting of personal belongings through packing, unpacking, resettling, and selling of items to the final clearing and cleaning of the property. For more information, visit http://www.caringtransitions.com or visit us on Facebook.

Media Contact

Mike Toper, 919 Marketing.com, (919) 813-6511, [email protected], 919marketing.com

SOURCE Caring Transitions

EQUASHIELD: The Leading Provider of Closed System Transfer Devices Celebrates Five Years as the Most Used Device in Hazardous Drug Administration and Preparation



Pharmacy Purchasing & Products Report Identified EQUASHIELD as Top Choice for Administration and Preparation PORT WASHINGTON, N.Y., Sept. 8, 2023 /PRNewswire/ — EQUASHIELD, a pioneer in closed system transfer devices (CSTDs) and automated pharmacy compounding solutions, is thrilled to…

The FSHD Society Celebrates Fulcrum’s Milestone in the Fight Against FSHD


In addition, the Society, along with other patient advocacy groups, helped found and launch Project Mercury, a global collaboration platform to address clinical trial readiness and patient access around the world. Fulcrum is a sustaining industry member of Project Mercury. Project Mercury is key to both the Society and Fulcrum’s ongoing work together. Mel Hayes, Chief Operations Officer of Fulcrum, commented on the FSHD Society’s contribution to the REACH trial: “As the global sustaining member of Project Mercury and a longtime collaborator with the FSHD Society, Fulcrum is excited to announce that we have reached a major milestone with completion of enrollment in the REACH Phase III clinical trial. This REACH milestone, coupled with Project Mercury’s global task force ambitions and the Society’s work to prepare the FSHD community for its potential first therapy for FSHD serves as an inflection point for the FSHD community.”

Fulcrum Therapeutics has successfully enrolled 260 patients in the REACH Phase 3 trial across nine countries in the United States, Canada, and Europe. The trial employs a rigorous, double-blind, placebo-controlled design to evaluate the efficacy and safety of losmapimod for FSHD treatment. Patients were randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or a placebo. Over a 48-week treatment period, various endpoints, including Reachable Workspace (RWS), muscle fat infiltration (MFI), Patient Global Impression of Change (PGIC), and Quality of Life in Neurological Disorders of the Upper Extremity (Neuro QoL UE), will be assessed. Moreover, REACH encompasses patient-centered evaluations of healthcare utilization.

Topline data from the Phase 3 REACH trial is anticipated to be reported in Q4 of 2024, bringing the FSHD community one step closer to the potential approval of the first-ever therapy for this challenging condition. Read the full press release from Fulcrum Therapeutics here.

Mark Stone, CEO of the FSHD Society, conveyed his excitement about the importance of this news for the FSHD community by stating, “This represents reaching a significant milestone and is a major step forward to providing safe and effective treatments for everyone living with FSHD! We are proud of our partnership with Fulcrum and the impact they are having on drug development in FSHD.”

About the FSHD Society
The FSHD Society is the world’s largest research-focused patient advocacy organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of MD. Over the past 32 years, the organization has catalyzed major advancements and worked to accelerate the development of treatments and a cure to end the pain, disability, and suffering endured by one million people worldwide who live with FSHD. The FSHD Society has transformed the landscape for FSHD research and is committed to making sure that no one faces this disease alone.

The Society offers a community of support, news, and information through its website at https://www.fshsociety.org.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, formerly FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com.

About Project Mercury
Project Mercury is an open collaboration among stakeholders from across the globe coming together to overcome the challenges that could slow or prevent effective FSHD therapies from getting to patients everywhere. This collaboration takes place at the global level through a Global Task Force and at the local level, through Country Working Groups. The Task Force and the Working Groups are all led by patient advocacy organizations of the World FSHD Alliance. This global-local approach ensures customization of Project Mercury’s work at the local level while sharing resources at the global level. More information about Project Mercury can be found at https://www.projectmercuryfshd.org.

Media Contact

June Kinoshita, FSHD Society, 781-301-6649, [email protected], https://www.fshdsociety.org

Twitter Facebook

SOURCE FSHD Society